These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 9511071)

  • 41. Comparative efficacies of quinupristin-dalfopristin, linezolid, vancomycin, and ciprofloxacin in treatment, using the antibiotic-lock technique, of experimental catheter-related infection due to Staphylococcus aureus.
    Giacometti A; Cirioni O; Ghiselli R; Orlando F; Mocchegiani F; Silvestri C; Licci A; De Fusco M; Provinciali M; Saba V; Scalise G
    Antimicrob Agents Chemother; 2005 Oct; 49(10):4042-5. PubMed ID: 16189078
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bactericidal activity of quinupristin-dalfopristin against Staphylococcus aureus: clindamycin susceptibility as a surrogate indicator.
    Fuchs PC; Barry AL; Brown SD
    Antimicrob Agents Chemother; 2000 Oct; 44(10):2880-2. PubMed ID: 10991879
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Activity of quinupristin/dalfopristin against Streptococcus pneumoniae in vitro and in vivo in the rabbit model of experimental meningitis.
    Tarasi A; Dever LL; Tomasz A
    J Antimicrob Chemother; 1997 May; 39 Suppl A():121-7. PubMed ID: 9511076
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacodynamics of vancomycin alone and in combination with gentamicin at various dosing intervals against methicillin-resistant Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model.
    Houlihan HH; Mercier RC; Rybak MJ
    Antimicrob Agents Chemother; 1997 Nov; 41(11):2497-501. PubMed ID: 9371356
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [MIC and MBC of quinupristin/dalfopristin of erythromycin-resistant MRSA strains isolated from clinical specimens].
    Młynarczyk G; Młynarczyk A; Szymanek K; Bilewska A; Pupek J; Luczak M
    Med Dosw Mikrobiol; 2006; 58(3):199-205. PubMed ID: 17340994
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In-vitro activity of quinupristin/dalfopristin, levofloxacin and moxifloxacin against fusidic acid and rifampicin-resistant strains of methicillin-resistant Staphylococcus aureus (MRSA) from Malaysian hospitals.
    Norazah A; Lim VK; Rohani MY; Kamel AG
    Med J Malaysia; 2005 Oct; 60(4):411-5. PubMed ID: 16570701
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Quinupristin/dalfopristin: a review of its activity in experimental animal models of infection.
    Carbon C
    J Antimicrob Chemother; 1997 May; 39 Suppl A():115-9. PubMed ID: 9511075
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A review of the in-vitro activity of quinupristin/dalfopristin against intracellular pathogens and mycoplasmas.
    Bébéar C; Bouanchaud DH
    J Antimicrob Chemother; 1997 May; 39 Suppl A():59-62. PubMed ID: 9511064
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations.
    Akins RL; Rybak MJ
    Antimicrob Agents Chemother; 2001 Feb; 45(2):454-9. PubMed ID: 11158740
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Studies of RP 59500 in vitro and in a rabbit model of aortic valve endocarditis caused by methicillin-resistant Staphylococcus aureus.
    Chambers HF
    J Antimicrob Chemother; 1992 Jul; 30 Suppl A():117-22. PubMed ID: 1399943
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus.
    Miró JM; García-de-la-Mària C; Armero Y; de-Lazzari E; Soy D; Moreno A; del Rio A; Almela M; Mestres CA; Gatell JM; Jiménez-de-Anta MT; Marco F;
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2373-7. PubMed ID: 17485502
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Comparative study of treatment with quinupristin-dalfopristin alone or in combination with gentamicin, teicoplanin, imipenem or levofloxacin in experimental endocarditis due to a multidrug-resistant Enterococcus faecium].
    Pérez Salmerón J; Martínez García F; Roldán Conesa D; Lorente Salinas I; López Fornás F; Ruiz Gómez J; Gómez Gómez J; Segovia Hernández M; Valdés Chávarri M
    Rev Esp Quimioter; 2006 Sep; 19(3):258-66. PubMed ID: 17099794
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Therapeutic effect of ME1036 on endocarditis experimentally induced by methicillin-resistant Staphylococcus aureus.
    Nagura J; Kijima K; Kurazono M; Takahata S; Sugano T; Tanaka Y; Hirai Y; Yamada K; Takayama Y; Shitara E; Yonezawa M
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3526-8. PubMed ID: 16048975
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In vitro activity of vancomycin, quinupristin/dalfopristin, and linezolid against intact and disrupted biofilms of staphylococci.
    El-Azizi M; Rao S; Kanchanapoom T; Khardori N
    Ann Clin Microbiol Antimicrob; 2005 Jan; 4():2. PubMed ID: 15638934
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center.
    Smith PF; Booker BM; Ogundele AB; Kelchin P
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):255-9. PubMed ID: 15935606
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Subinhibitory quinupristin/dalfopristin attenuates virulence of Staphylococcus aureus.
    Koszczol C; Bernardo K; Krönke M; Krut O
    J Antimicrob Chemother; 2006 Sep; 58(3):564-74. PubMed ID: 16895938
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparative efficacies of imipenem-cilastatin and vancomycin in experimental aortic valve endocarditis due to methicillin resistant Staphylococcus aureus.
    Chandrasekar PH; Levine DP; Price S; Rybak MJ
    J Antimicrob Chemother; 1988 Apr; 21(4):461-9. PubMed ID: 3378959
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.
    Lamb HM; Figgitt DP; Faulds D
    Drugs; 1999 Dec; 58(6):1061-97. PubMed ID: 10651391
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment of vancomycin-resistant Enterococcus faecium infections with an investigational streptogramin antibiotic (quinupristin/dalfopristin): a report of fifteen cases.
    Dever LL; Smith SM; Dejesus D; Masurekar M; Patel D; Kaminski ZC; Johanson WG
    Microb Drug Resist; 1996; 2(4):407-13. PubMed ID: 9158811
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In vitro activity of quinupristin/dalfopristin, RP59500, against gram-positive clinical isolates.
    Qadri SM; Ueno Y; Abu Mostafa FM; Halim M
    Chemotherapy; 1997; 43(2):94-9. PubMed ID: 9084917
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.